CD8A and melanoma: In preclinical melanoma models, the combination of Ganetespib and a CTLA-4 inhibitor has shown anticancer effects in melanoma and colon cancer models through a decrease in immunosuppressive regulatory T cells and an increase in the antitumor activity of CD8+ T cells [120].